Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (BEIGF) Net Margin (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Net Margin for 11 consecutive years, with 4.44% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 1791.0% to 4.44% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5.37% through Dec 2025, up 2229.0% year-over-year, with the annual reading at 5.37% for FY2025, 2229.0% up from the prior year.
  • Net Margin for Q4 2025 was 4.44% at BeOne Medicines, down from 8.84% in the prior quarter.
  • The five-year high for Net Margin was 27.57% in Q3 2023, with the low at 320.24% in Q2 2021.
  • Average Net Margin over 5 years is 79.48%, with a median of 45.67% recorded in 2024.
  • The sharpest move saw Net Margin soared 74050bps in 2021, then crashed -15291bps in 2022.
  • Over 5 years, Net Margin stood at 276.04% in 2021, then soared by 58bps to 117.16% in 2022, then soared by 51bps to 57.94% in 2023, then surged by 77bps to 13.47% in 2024, then skyrocketed by 133bps to 4.44% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 4.44%, 8.84%, and 7.17% for Q4 2025, Q3 2025, and Q2 2025 respectively.